WATERTOWN, Mass.--(BUSINESS WIRE)--Selecta Biosciences, Inc. has obtained an exclusive license to Anc80, an in silico designed gene therapy vector, from Massachusetts Eye and Ear for a rare genetic disease with additional options.
![]()
↧